How Can We Help?
You are here:
< Back

Fuzuloparib (trade name AiRuiYi) is a pharmaceutical drug for the treatment of ovarian cancer.[1] It is approved for use in China.[2] It is an inhibitor of the poly (ADP-ribose) polymerase (PARP) enzyme.[3]

It is also being studied for its potential use for the treatment of pancreatic, breast, prostate, and lung cancer.[2]

References

  1. ^ Li N, Liu Q, Tian Y, Wu L (November 2022). "Overview of fuzuloparib in the treatment of ovarian cancer: background and future perspective". Journal of Gynecologic Oncology. 33 (6): e86. doi:10.3802/jgo.2022.33.e86. PMC 9634097. PMID 36335989.
  2. ^ a b Lee A (July 2021). "Fuzuloparib: First Approval". Drugs. 81 (10): 1221–1226. doi:10.1007/s40265-021-01541-x. PMC 8380563. PMID 34118019.
  3. ^ "Fuzuloparib - Jiangsu HengRui Medicine". AdisInsight. Springer Nature Switzerland AG.
Categories
Table of Contents